METHOD FOR TREATING ONCOLOGICAL DISEASES

The invention belongs to the field of medicine, in particular, to the methods for treating the patients with the preparations containing genetic material, and may be used for treating the patients with oncologic diseases caused by mutations in oncogenes, oncosuppressor genes, and a total gene allele...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Hauptverfasser:	ZHDANOVA, NATALIA SERGEEVNA, VRATSKIKH, OXANA VYACHESLAVOVNA, SHILOV, ALEXANDER GENNADIEVICH, YAKUBOV, LEONID ANATOLIEVICH, SEREGIN, SERGEY NIKOLAEVICH, ROGACHEV, VLADIMIR ALEXEEVICH, MECHETINA, LJUDMILA VASILIEVNA, POPOVA, NELLY ALEXANDROVNA, LIKHACHEVA, ANASTASIA SERGEEVNA, SEBELEVA, TAMARA EGOROVNA, BOGACHEV, SERGEY STANISLAVOVICH, NIKOLIN, VALERY PETROVICH
Format:	Patent
Sprache:	eng ; fre ; ger
Schlagworte:	HUMAN NECESSITIES HYGIENE MEDICAL OR VETERINARY SCIENCE PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS
Online-Zugang:	Volltext bestellen
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Beschreibung
Zusammenfassung:	The invention belongs to the field of medicine, in particular, to the methods for treating the patients with the preparations containing genetic material, and may be used for treating the patients with oncologic diseases caused by mutations in oncogenes, oncosuppressor genes, and a total gene allele homozygotization of the cell that undergoes a malignant transformation. The stated problem consisting in expansion of the area of application and treatment of patients with oncologic diseases caused by both the mutations in oncogenes and oncosuppressor genes and a total gene homozygotization is solved by that the fragments of homologous DNA comprising the complete genome of a physiologically and genetically healthy donor are introduced into the patient's organism and the quantity of the DNA introduced is equal to or exceeds the amount of the own DNA in the blood plasma and tissue fluids, but does not exceed the maximal permissible dose, amounting to 30 µg/ml.